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Supplemental Methods
The development of these guidelines was a multistep process, consisting in: 
Systematic review of the literature and synthesis of evidence
A systematic review of the literature has been performed according to the following criteria:
•English language;
•Year of publication: 1985-2012;
•Studies including 10 patients or more;
•Source: PubMed (1985 PubMed ( -2012 
Key questions and list of indications
The guidelines were developed based on a list of patient-and therapy-oriented questions.
A list of key clinical questions clinical key-questions were generated and rank-ordered using the criterion of clinical relevance, pointing to the proper diagnostic procedures and the possible and recommendable strategies within each therapeutic category, to the possible and optimal patient subgroups, and to the risks deriving from the therapy.
The Expert Panel was invited to formulate evidence-based statements for each clinical question in an independent manner. Based on the statements of the experts for each question, the clinical variables will be defined that have to be taken into account in deciding whether to recommend a particular procedure (list of indications).
Scenario analysis
A scenario analysis is a procedure aimed at reaching a consensus on the indication of a certain treatment or procedure, in case scientific evidence is not at a level of detail sufficient enough to sustain everyday clinical decision. Therefore a method was defined that allows to combine the best available scientific evidence with the collective judgment by experts to yield a statement regarding the appropriateness of performing a procedure at the level of patient-specific symptoms, medical history and test results (i.e. clinical scenario).
To this aim, a series of clinical scenarios were defined based on the parameters relevant to therapy choice. For each clinical scenario (i.e. patient case) the members of the Expert
Panel were asked to grade the appropriateness of performing a certain procedure or providing a certain treatment according to a scale from 1 to 9, where 1 indicates that the questioned strategy is highly inappropriate, and 9 that it is highly appropriate.
A procedure or treatment is considered to be appropriate if "the expected health benefit (e.g., increased life expectancy, relief of pain, reduction in anxiety, improved functional capacity) exceeds the expected negative consequences (e.g., mortality, morbidity, anxiety, pain, time lost from work) by a sufficiently wide margin that the procedure is worth doing, exclusive of cost." 3 Although cost considerations are an important factor in deciding whether a procedure or treatment should ultimately be made available to patients, this discussion must include a broader group of individuals (physicians, consumers, payers), and has to take place once physicians have judged a treatment or procedure as effective.
A cost-effectiveness analysis is outside the scope of this project, and should be committed to national working groups.
The appropriateness of providing a treatment or procedure is different from the necessity of performing it. The necessity is a more stringent criterion than appropriateness. A procedure is considered necessary when all the following criteria are met: (i) the procedure must be appropriate; (ii) it would be considered improper care not to provide this service;
(iii) there is a reasonable chance that the procedure will benefit the patient (a procedure could be appropriate if it had a low likelihood of benefit but few risks; such procedure would not be necessary); (iv) the benefit to the patient is not small (a procedure could be appropriate if it had a minor but almost certain benefit, but it would not be necessary).
Rating the necessity of providing a treatment is outside the scope of this analysis.
Then, an analysis of the panelists' scores was carried out (median, dispersion of ratings)
with the aim at defining the level of agreement (agreement, indeterminate, disagreement) and the appropriateness rating (appropriate, uncertain, inappropriate).
Formulation of recommendations
Based on evidence from the literature, question-specific statements and scenario analysis final recommendations will be formulated. Three consensus conferences were held to reach a definite consensus. 4 Recommendations were formulated and ranked according to the supporting level of evidence. All complete remission criteria if abnormal before treatment except:
• Bone marrow blasts decreased by ≥ 50% over pretreatment but still >5%
• Cellularity and morphology not relevant
Marrow complete remission †
Bone marrow: ≤ 5% myeloblasts and decrease by ≥50% over pretreatment
Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow complete remission
Stable disease
Failure to achieve at least partial remission, but no evidence of progression for > 8 weeks
Failure
Death during treatment or disease progression characterized by worsening of cytopenias, increase in percentage of bone marrow blasts, or progression to a more advanced MDS FAB subtype than pretreatment
Relapse after CR or PR
At least 1 of the following: § Return to pretreatment bone marrow blast percentage § Decrement of ≥50% from maximum response levels in granulocytes or platelets § Reduction in hemoglobin concentration by ≥1.5 g/dL or transfusion dependence
Cytogenetic response †
Complete: disappearance of the chromosomal abnormality without appearance of new ones Partial: at least 50% reduction of the chromosomal abnormality
Disease progression
For patients with: § Less than 5% blasts: ≥ 50% increase in blasts to > 5% blasts § 5%-10% blasts: ≥ 50% increase to > 10% blasts § 10%-20% blasts: ≥ 50% increase to > 20% blasts § 20%-30% blasts: ≥ 50% increase to > 30% blasts Any of the following: § At least 50% decrement from maximum response in granulocytes or platelets § Reduction in hemoglobin by ≥ 2 g/dL
